Table 3.
Summary of TE arrhythmias analyzed by ASA Physical Class stratum. All Participants as Treated
| Treatment | ASA Physical Class 3 | ASA Physical Class 4 | ||||
|---|---|---|---|---|---|---|
| n (%) | Estimate (95% CI) | P-value | n (%) | Estimate (95% CI) | P-value | |
| TE Sinus Bradycardia | ||||||
| Neostigmine/glycopyrrolate, n = 38a, 13b | 2 (5.3) | (ref.) | 2 (15.4) | (ref.) | ||
| Sugammadex 2 mg/kg, n = 79a, 26b | 1 (1.3) | −4.0 (−16.2, 2.5) | 0.202 | 0 | −15.4 (− 42.6, − 0.9) | 0.043 |
| Sugammadex 4 mg/kg, n = 79a, 28b | 1 (1.3) | − 4.0 (− 16.2, 2.5) | 0.202 | 1 (3.6) | −11.8 (−39.6, 5.9) | 0.182 |
| Sugammadex 16 mg/kg, n = 51a, 17b | 4 (7.8) | 2.6 (− 10.5, 14.3) | 0.633 | 1 (5.9) | −9.5 (− 38.1, 15.2) | 0.398 |
| TE Sinus Tachycardia | ||||||
| Neostigmine/glycopyrrolate, n = 38 | 7 (18.4) | (ref.) | 4 (30.8) | (ref.) | ||
| Sugammadex 2 mg/kg, n = 79 | 5 (6.3) | −12.1 (−27.8, −0.3) | 0.044 | 2 (7.7) | −23.1 (−51.7, 1.2) | 0.063 |
| Sugammadex 4 mg/kg, n = 79 | 10 (12.7) | −5.8 (− 22.1, 7.4) | 0.409 | 0 | −30.8 (− 57.9, − 12.5) | 0.002 |
| Sugammadex 16 mg/kg, n = 51 | 5 (9.8) | −8.6 (− 25.1, 5.9) | 0.242 | 1 (5.9) | −24.9 (− 53.6, 2.8) | 0.075 |
| Other TE Cardiac Arrhythmias | ||||||
| Neostigmine/glycopyrrolate, n = 38 | 0 | (ref.) | 1 (7.7) | (ref.) | ||
| Sugammadex 2 mg/kg, n = 79 | 0 | 0.0 (−9.3, 4.7) | > 0.999 | 1 (3.8) | −3.8 (− 30.4, 13.0) | 0.612 |
| Sugammadex 4 mg/kg, n = 79 | 0 | 0.0 (−9.3, 4.7) | > 0.999 | 0 | −7.7 (−33.7, 5.3) | 0.142 |
| Sugammadex 16 mg/kg, n = 51 | 0 | 0.0 (−9.3, 7.1) | > 0.999 | 1 (5.9) | −1.8 (− 29.0, 21.3) | 0.846 |
aNumber of participants in ASA Physical Class 3 stratum; bnumber of participants in ASA Physical Class 4 stratum; ASA American Society of Anesthesiologists, CI Confidence interval, TE Treatment-emergent